U.S. study suggests that semaglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist, may be useful to reduce alcohol consumption and craving in alcohol use disorder.
Study examines the comparative cardiovascular efficacy and safety of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with type 2 diabetes.
Imbalances caused by PCOS put women at risk for metabolic syndrome, but the condition continues to be misdiagnosed, says Ontario physician Dr. Ashley White.
Health Canada has reviewed evidence on the link between glucagon-like peptide-1 (GLP-1) receptor agonists and suicide, self-harm and suicidal/self-harm ideation.
